THERAPEUTIC MANAGEMENT OF MENOPAUSE: HORMONAL APPROACH AND NON-HORMONAL ALTERNATIVES
DOI:
https://doi.org/10.56238/isevmjv5n1-020Keywords:
Menopause, Hormone Therapy, Non-Hormonal Alternatives, Vasomotor Symptoms, Genitourinary Syndrome of Menopause, Anti-Müllerian HormoneAbstract
Menopause is a physiological milestone characterized by the loss of ovarian follicular activity, often associated with vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM). Although Menopausal Hormone Therapy (MHT) is the most effective intervention for symptomatic relief and prevention of bone loss, its use is limited by contraindications in specific subgroups, such as breast cancer survivors and patients with a history of endometriosis, requiring individualized approaches. Diagnosis is clinical and retrospective, but Anti-Müllerian Hormone (AMH) is a sensitive biomarker of ovarian reserve, useful in predicting impending menopause, despite persistent inaccuracy in determining the exact timing. Advances in non-hormonal alternatives represent a promising frontier, including neurokinin receptor antagonists such as fezolinetant and elinzanetant for VMS, and topical therapies such as vaginal hyaluronic acid and laser (CO2 and Er:YAG) for GSM/vulvovaginal atrophy, which demonstrate comparable efficacy in patient-centered outcomes, with favorable safety profiles for patients at oncologic risk. In addition, MHT has been shown to optimize weight loss response when combined with GLP-1 agonists such as semaglutide. However, therapeutic management of menopause still lacks long-term data regarding the cardiovascular, skeletal, and oncologic safety of new non-hormonal therapies, reinforcing the need for prospective studies to consolidate safe and individualized strategies during the climacteric period.
References
Agrawal, S., et al. (2024). A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause, 31(9), 750–755. https://doi.org/10.1097/GME.0000000000002390
Benini, V., Ruffolo, A. F., Casiraghi, A., Degliuomini, R. S., Frigerio, M., Braga, A., Serati, M., Torella, M., Candiani, M., & Salvatore, S. (2022). New innovations for the treatment of vulvovaginal atrophy: An up-to-date review. Medicina, 58(6), Article 770. https://doi.org/10.3390/medicina58060770
Cassani, C., et al. (2024). Menopause and endometriosis. Maturitas, 190, Article 108129. https://doi.org/10.1016/j.maturitas.2024.108129
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023). Management of menopausal symptoms: A review. JAMA, 329(5), 405–420. https://doi.org/10.1001/jama.2022.24140
Glynne, S., et al. (2026). Menopausal hormone therapy for breast cancer patients: What is the current evidence? Menopause, 33(1), 88–117. https://doi.org/10.1097/GME.0000000000002627
Gold, E. B. (2011). The timing of the age at which natural menopause occurs. Obstetrics and Gynecology Clinics of North America, 38(3), 425–440. https://doi.org/10.1016/j.ogc.2011.05.002
Golezar, S., Ramezani Tehrani, F., Khazaei, S., Ebadi, A., & Keshavarz, Z. (2019). The global prevalence of primary ovarian insufficiency and early menopause: A meta-analysis. Climacteric, 22(4), 403–411. https://doi.org/10.1080/13697137.2019.1573220
Hurtado, M. D., et al. (2024). Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause, 31(4), 266–274. https://doi.org/10.1097/GME.0000000000002310
Johnson, K. A., et al. (2023). Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: A phase 3 RCT. The Journal of Clinical Endocrinology & Metabolism, 108(8), 1981–1997. https://doi.org/10.1210/clinem/dgad058
Karaviti, E., et al. (2025). The role of anti-Müllerian hormone: Insights into ovarian reserve, primary ovarian insufficiency, and menopause prediction. Endocrine, 89(2), 338–355. (DOI não localizado na busca; adicione se disponível via PubMed.)
Nelson, S. M., et al. (2023). Anti-Müllerian hormone for the diagnosis and prediction of menopause: A systematic review. Human Reproduction Update, 29(3), 327–346. https://doi.org/10.1093/humupd/dmad001
Panay, N., et al. (2024). Elinzanetant for the treatment of vasomotor symptoms associated with menopause: A phase 3 randomized clinical trial. JAMA Internal Medicine. Advance online publication.
Schoenaker, D. A. J. M., Jackson, C. A., Rowlands, J. V., & Mishra, G. D. (2014). Socioeconomic position, lifestyle factors and age at natural menopause: A systematic review and meta-analyses of studies across six continents. International Journal of Epidemiology, 43(5), 1542–1562. https://doi.org/10.1093/ije/dyu094
Shuster, L. T., Rhodes, D. J., Gostout, B. S., Grossardt, B. R., & Rocca, W. A. (2010). Premature menopause or early menopause: Long-term health consequences. Maturitas, 65(2), 161–166. https://doi.org/10.1016/j.maturitas.2009.08.003
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
